Isomorphic Labs has raised a $5 billion Series C round. The AI drug design company announced the financing on November 17, 2026. Greenoaks and Sequoia Capital co-led the round.
Participating investors
Andreessen Horowitz and several other new investors joined the round. Alphabet made a continued significant investment. Existing backers Thrive Capital, MGX, GV, CapitalG, Temasek, and the UK Sovereign AI Fund also participated.
Company background
Isomorphic Labs was founded in 2021. Sir Demis Hassabis serves as CEO, and Max Jaderberg serves as president. The company is based in London with offices in Cambridge, Massachusetts, and Lausanne, Switzerland.
What IsoDDE does
IsoDDE unifies a suite of simulation AI models. It works across multiple therapeutic areas and drug modalities. The company reports positive preclinical results in oncology and immunology, including partner programs.
The company will use the new capital to mature IsoDDE and expand into new biology. It plans to build global infrastructure for AI-led bioengineering. Isomorphic Labs also aims to advance its first therapeutic candidates into clinical trials.